Executive Management

The Board of Directors and the Executive managements shareholings are as of February 28, 2010 and include family members and shares held through companies. Information regarding options refers to the number of shares the options held represent.

FREDRIK LINDGREN (1971)
President and Chief Executive Officer
Employed by Karo Bio since April 23, 2010.
Education: Law degree from Lund University; basic university studies in Philosophy and Business Administration; Certified European Financial Analyst at Stockholm School of Business
Primary experience: Since the early 90-ies responsible for strategic operations such as reengineering, funding, acquisitons of companies in the biotech sector, among others. Former employers include Active Biotech AB, Meaning Green AB, MidelfartSonesson and Biolin Scientific AB.
Other engagements: Board member in Biolin Scientific AB, Connect Skåne, Genovis AB, Mecena and ProstaLund AB.
Shares in Karo Bio: 500,000
Employee stock options: none

Berit Edlund (1948)
Director Human Resources
Employed by Karo Bio since 2001
Education: B.A. in social work
Previous assignments: Long HR expericene within a number of different sectors, including the public sector, IT, telecom and pharmaceuticals. Previous employers include Skandia, Ericsson, Pharmacia and Huawei.
Shares in Karo Bio: 8,966
Options in Karo Bio: 5,059

Anneli Hällgren (1965)
Chief Scientific Officer, VP Preclinical Research and Development
Employed by Karo Bio since 2006
Education: Ph.D., M.Sc.Pharm
Previous assignments: Head of preclinical development, Biolipox AB (2003-2006). Head of In vivo pharmacology, Melacure Therapeutics AB (2001-2003), senior researcher and preclinical project leader, AstraZeneca (1997-2001).
Shares in Karo Bio: 23,400
Options in Karo Bio: none

Erika Söderberg Johnson (1970)
Chief Financial Officer, VP Finance and Investor Relations
Employed by Karo Bio since 2007
Education: M.Sc. Business Administration, Stockholm School of Economics
Previous assignments: Chief Financial Officer, Affibody AB (2005-2007) and Global Genomics AB (2002-2005). Nine years experience from investment banking within SEB Enskilda Securities Corporate Finance (1993-2002).
Other current assignments: Board member of Sectra AB since 2007
Shares in Karo Bio: 14,000
Options in Karo Bio: none

Jens Kristensen (1958)
Chief Medical Officer, VP Clinical Development and Regulatory Affairs
Employed by Karo Bio since 2005
Education: Ph.D., M.D.
Previous assignments: Worked as a physician for 16 years, and thereafter eleven years within the pharmaceutical industry. Previous employers include AstraZeneca (2004-2005 and 1998-2001) and Melacure Therapeutics AB (2002-2004).
Shares in Karo Bio: 23,305
Options in Karo Bio: none

Lars Öhman (1957)
VP Business Development
Employed by Karo Bio since 1989
Education: MBA, Stockholm School of Economics; Chemical Engineering, Royal Institute of Technology, Stockholm
Previous assignments: Project leader and other senior assignments within Karo Bio's research and development organisation.
Shares in Karo Bio: 16,264
Options in Karo Bio: 3,186